Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYNT-213
- Development stage
- Preclinical
- Lead developer
- Syntis Bio
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
SYNT-213 is an oral, gastrointestinal (GI)-stable enzyme replacement therapy being developed by Syntis Bio for the treatment of Maple Syrup Urine Disease (MSUD). The therapeutic consists of the enzyme leucine decarboxylase (LDC) engineered for stability in the gut environment and delivered using the proprietary DIGEST™ platform for extended release. SYNT-213 works by degrading leucine from both dietary sources and enteric elimination within the GI tract, thereby reducing the systemic accumulation of this amino acid and its toxic byproducts, which are the primary drivers of neurological damage in MSUD patients.
- Other names
- leucine decarboxylaseLDC
Beyond the preview
Go deeper on SYNT-213.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYNT-213.